← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Ventrix, Inc.
Grand Junction, CA
$5,520,638
Total funding
5
Grants
Funding over time
peak $1.4M · FY2010–24$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,340,638 · 4
NSF$180,000 · 1
By mechanism
R44$4,052,165 · 2
R43$1,288,473 · 2
—$180,000 · 1
Investigators at Ventrix, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Pivotal Preclinical Studies of Novel Infusible ECM for Treating Acute MI$1,440,231
R44 · FY2024 · HL
Phase II: Percutaneous deliverable biomaterial for treating myocardial infarction$1,339,549
R44 · FY2013 · HL
New infusible ECM hydrogel for treating acute myocardial infarction$791,543
R43 · FY2020 · HL
Phase II: Percutaneous deliverable biomaterial for treating myocardial infarction$720,276
R44 · FY2014 · HL
Pivotal Preclinical Studies of Novel Infusible ECM for Treating Acute MI$552,109
R44 · FY2023 · HL
Percutaneous deliverable biomaterial for treating myocardial infarction$496,930
R43 · FY2011 · HL
SBIR Phase I: Feasibility of a minimally-invasive biomaterial therapy for heart failure$180,000
· FY2010 · TIP